Most AEs were of mild to moderate intensity and comparable to placebo. The most common AEs reported were: epistaxis, headache, nasopharyngitis, laryngopharyngeal pain.
The efficacy of FFNS for individual symptoms is consistent across different pollen allergy seasons, geographical locations, and ethnicity of the patients with SAR. 1
* Integrated analysis performed on data from 4 randomised, double-blind, placebo-controlled, parallel-group, multicentre trials, which were designed to evaluate the efficacy and safety of FFNS for 14 days in 1141 adult and adolescent seasonal AR patients. The primary efficacy measure for each study was the mean change from baseline over the entire treatment period in daily rTNSS.
† Global, randomised, double-blind, placebo-controlled, 6-week study evaluating the efficacy and tolerability of intranasal fluticasone furoate in patients ≥12 years of age (n=302) with perennial AR. The primary efficacy measure was mean change from baseline over the 6-week treatment period in daily reflective TNSS.
AR: allergic rhinitis, FFNS: fluticasone furoate nasal spray, rTNSS: reflective total nasal symptom score, INCS: intranasal corticosteroid; SAR: seasonal allergic rhinitis, rTOSS: reflective total ocular symptom score.
- Maspero JF, Walters RD, Wu W, et al. An integrated analysis of the efficacy of fluticasone furoate nasal spray on individual nasal and ocular symptoms of seasonal allergic rhinitis. Allergy Asthma Proc. 2010;31(6):483-492.
- Vasar M, Houle PA, Douglass JA, et al. Fluticasone furoate nasal spray: Effective monotherapy for symptoms of perennial allergic rhinitis in adults/adolescents. Allergy Asthma Proc. 2008;29(3);313-321.
- Valotis A, Hogger P. Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate. Respir Res. 2007;8(1):54.